Cooley LLP

Cooley advised clinical-stage biopharmaceutical company Kura Oncology, Inc. on its global strategic collaboration with Kyowa Kirin to develop and commercialize ziftomenib, Kura’s selective oral menin inhibitor that is being investigated for the treatment of acute myeloid leukemia (AML) and other hematologic malignancies. Congratulations to Kura and to the Cooley team, led by Charity Williams, Chen Chen, Jonathan Kaufman, Aaron Pomeroy, Todd Gluth, Amanda Pacheco, Howard Morse, David Burns, Charles Bair and Andrew Epstein. ?? Read more here: https://bit.ly/3OoSxsM

Check out Cooley's October pubic companies update for insight on the SEC's adoption of final rules implementing EDGAR Next, Fidelity's proxy voting guidelines, amendments to the requirements of California’s climate disclosure bills + more. ?? Read more here: https://bit.ly/4eFSmEq

Ethan Glass, Cooley partner and chair of the firm’s antitrust and competition practice group, appeared as a guest on an episode of the “Tech Talk with 20for20” podcast, where he discussed the complexities of antitrust law in the housing market and provided an overview on legal actions against multifamily revenue management. ??? Listen to the episode here: https://bit.ly/3V2AJHX #CooleyREG #antitrust

Cooley's "Legal Insights: A CLE Webinar Series" kicks off this December, providing audiences with a legal education program focused on a variety of newsworthy business and litigation topics. Specialty credits in the areas of ethics, technology, civility and wellness also will be offered. ?? See the full lineup here: https://bit.ly/3UUdU9a

Cooley lawyers Bobby Ghajar, Judd Lauter and Jessica Williams were featured on Law360's Legal Lions of the Week list for securing a favorable preliminary injunction on behalf of the City and County of San Francisco, barring the Port of Oakland from using “San Francisco Bay” in its international airport’s new name. Congratulations, all! Read more here: https://bit.ly/3OhefPC

Cooley partner Susanne Sachsman Grooms spoke with Law.com on the potential changes that congressional investigations will see under the Trump administration. ?? Subscribers can read the article here: https://bit.ly/3OeElCN #CooleyREG

Cooley advised Geron Corporation, a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, on its up to $375 million in synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors. Congratulations to Geron and to the Cooley team led by Mischi aMarca, Shimeng Cheng, Addison Pierce, Chad Mills, Jon Cousin, Alexander (Xander) Lee and Jennifer Raab. ?? Read more here: https://bit.ly/3UXTFau

Cooley lawyers Matt Howsare and Elliot F. Kaye will be providing insights and analysis during a December 3 webinar, where they will discuss the US Consumer Product Safety Commission's increasingly bold enforcement action and discussing where the CPSC will focus in 2025, plus how to stay ahead. ?? Learn more here: https://bit.ly/3AZANRI

Many US companies are within the scope of reporting requirements for the European Union's Corporate Sustainability Reporting Directive (CSRD) as of fiscal year 2025. The Corporate Sustainability Due Diligence Directive (CSDDD) requires these same companies to adopt a climate transition plan starting in 2027. ?? For more on EU regulatory reporting requirements, watch the video below and hear from environmental, social and governance (ESG) lawyers Beth Sasfai, Michael Mencher and Emma Bichet.

Since 2019, Cooley has welcomed more than 40 litigation partners, established robust appellate and congressional investigations practices, and launched CooleyREG to navigate evolving regulations. Partner and litigation department chair, Michael Attanasio, spoke with Law360 about the team's growth strategy and how Cooley has solidified its position at the intersection of law and technology. ?? Read the full article below.